| Dosing Regimens and Related Compositions and Methods |
2023-4-12 |
2023-7-19 |
|
| Cell-reactive, long-acting, or targeted compstatin analogs and related … |
2023-2-17 |
2023-3-23 |
|
| Rnas for complement inhibition |
2022-12-23 |
2023-7-06 |
|
| Complement inhibitor dosing regimens |
2022-11-03 |
2023-5-11 |
|
| Systems and methods for virtual reality, augmented reality, and mixed reality … |
2022-10-21 |
2023-4-27 |
|
| Compositions and methods for genome editing the neonatal fc receptor |
2022-10-13 |
2023-4-20 |
|
| Treatment of geographic atrophy |
2022-9-09 |
2023-4-13 |
|
| Combination therapy for C3 inhibition |
2022-9-09 |
2022-12-20 |
|
| Complement inhibition |
2022-6-30 |
2023-1-05 |
|
| Cell-penetrating compstatin analogs and uses thereof |
2022-6-29 |
2023-3-09 |
|
| Genomic editing of complement |
2022-5-26 |
2022-12-29 |
|
| Treatment of complement-mediated disorders |
2022-5-26 |
2022-12-01 |
|
| Polypeptides for complement inhibition |
2022-3-18 |
2022-9-22 |
|
| Genomic editing of complement |
2021-12-10 |
2023-7-06 |
|
| Methods of treating eye disorders |
2021-9-22 |
2022-4-16 |
|
| Methods and compositions for cancer treatment and treatment selection |
2021-9-21 |
2022-8-11 |
|
| Rnas for complement inhibition |
2021-8-18 |
2023-3-01 |
|
| Compositions and methods relating to c5l2 |
2021-6-22 |
2022-3-24 |
|
| Methods of treating chronic disorders with complement inhibitors |
2021-4-20 |
2023-8-01 |
2023-8-01 |
| Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof |
2021-3-17 |
2023-5-30 |
2023-5-30 |
| Rnas for complement inhibition |
2021-2-13 |
2021-10-21 |
|
| Treatment of paroxysmal nocturnal hemoglobinuria |
2021-1-07 |
2022-10-25 |
|
| Complement inhibitor dosing regimens |
2020-7-17 |
2022-9-08 |
|
| Viral vector therapy |
2020-7-02 |
2023-7-12 |
|
| Compstatin analogs for treatment of neuropathic pain |
2020-6-09 |
2021-4-15 |
|
| RNAs for complement inhibition |
2020-4-20 |
2022-11-29 |
2022-11-29 |
| Detection of high risk drusen |
2020-4-03 |
2020-12-10 |
|
| Cell-reactive, long-acting, or targeted compstatin analogs and related … |
2019-10-18 |
2020-10-15 |
|
| Dosing regimens |
2019-2-01 |
2019-11-29 |
|
| Administration regimen and related compositions and methods |
2018-12-14 |
2021-2-25 |
|
| Treatment of disorders |
2018-10-30 |
2020-11-12 |
|
| Local complement inhibition for treatment of complement-mediated disorders |
2017-11-21 |
2018-11-22 |
|
| Compstatin or its analogs for ocular disorders |
2017-7-06 |
2017-12-28 |
|
| Compstatin analogs for treatment of rhinosinusitis and nasal polyposis |
2017-6-15 |
2018-5-03 |
|
| Modifying macrophage phenotype for treatment of disease |
2017-5-16 |
2018-1-04 |
|
| Compstatin and analogs thereof for eye disorders |
2017-1-06 |
2017-12-07 |
|
| Injectable combination therapy for eye disorders |
2016-11-04 |
2016-11-24 |
|
| Complement assays and uses thereof |
2016-2-09 |
2016-6-02 |
|
| Systems and methods for assembling electronic medical records |
2012-11-08 |
2013-5-16 |
|
| Apparatus and methods for assisting breathing |
2012-1-25 |
2015-11-03 |
2015-11-03 |
| Viral Complement Control Proteins for Eye Disorders |
2011-10-03 |
2013-3-21 |
|
| Methods and articles for preventing or reducing risk of developing a … |
2011-5-02 |
2017-8-08 |
2017-8-08 |
| Methods, articles and kits for allergic desensitization, via the oral mucosa |
2011-5-02 |
2016-3-01 |
2016-3-01 |
| Modulation and repletion/enhancement of the complement system for treatment of … |
2009-3-30 |
2011-8-04 |
|
| Sustained delivery of compstatin analogs from gels |
2008-10-02 |
2010-10-06 |
|
| Compositions and methods for treatment of trauma |
2008-7-21 |
2011-4-21 |
|
| Compositions comprising modulators of G-protein-coupled receptor for treatment … |
2006-3-13 |
2006-9-21 |
|
| Viral complement control proteins for eye disorders |
2005-10-08 |
2006-6-29 |
|
| Compositions and methods for enhancing phagocytosis or phagocyte activity |
2004-8-23 |
2005-5-26 |
|